SHANGHAI, China, July?15, 2026, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the preliminary positive research results of IIT (CT041-CG4010, NCT06857786) in China of satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product against Claudin18.2), as consolidation therapy following adjuvant treatment for locally advanced gastric or gastroesophageal junction cancer, has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026. The abstract will be published on the ESMO website at 00:05 Central European Summer Time (CEST) on Monday, October 19, 2026.
?
Since the initiation of patient enrollment in May 2025 for the CT041-CG4010 trial, up to the date of this press release, none of the participants receiving satri-cel have experienced postoperative recurrence or metastasis of gastric cancer.
?
About Satri-cel
Satri-cel is an autologous CAR T-cell therapy product against the protein Claudin18.2 that is the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors. It was approved by the NMPA in June 2026 for the treatment of Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy, making it the world’s first approved CAR T-cell therapy product for solid tumors.
?
The Company is actively expanding satri-cel application in early-line treatment and perioperative treatment of cancer, including an ongoing Phase I clinical trial for pancreatic cancer adjuvant therapy in China (NCT05911217), an IIT for consolidation treatment following adjuvant therapy in patients with resected G/GEJA (NCT06857786) and an IIT for sequential therapy following first-line treatment for G/GEJA (NCT07179484).
?
About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.
?
Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, . No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.
?
Contact CARsgen
For more information, please visit /
Public Relations: PR@carsgen.com
Investor Relations: IR@carsgen.com